# Eplerenone

## Inspra FC 50mg

| 藥物代碼 | OINS |
| :--- | :--- |
| 適應症 | Post-MI heart failure patients & patients w/ NYHA class II \(chronic\) heart failure. |
| 副作用 | Infection; hyperkalaemia; dizziness, syncope; MI; hypotension; diarrhoea, nausea, constipation; rash, pruritus; muscle spasms, musculoskeletal pain; renal impairment; increased BUN, cough. |
| 禁忌 | Hypersensitivity. Patient w/ serum K level &gt;5 mmol/L at initiation; severe renal insufficiency \(eGFR &lt;30 mL/min/1.73 m2\); severe hepatic insufficiency \(Child-Pugh class C\); those receiving K-sparing diuretics, K supplements or strong CYP3A4 inhibitors \(eg, itraconazole, ketoconazole, ritonavir, nelfinavir, clarithromycin, telithromycin & nefazodone\). Combination w/ ACE inhibitors & angiotensin-receptor blockers \(ARB\). Patient w/ HTN, type 2 diabetes w/ microalbuminuria & serum creatinine &gt;2 mg/dL \(males\) or &gt;1.8 mg/dL \(females\). |
| 藥物保存方式 | 室溫 |
| 用法用量 | Heart failure - Myocardial infarction with complication ‧initial, 25 mg ORALLY once daily; titration preferably within 4 weeks to 50 mg ORALLY once daily. Hypertension ‧initial, 50 mg ORALLY once daily; allow 4 weeks to achieve optimum antihypertensive effect; may increase to MAX 50 mg ORALLY twice daily for inadequate response Systolic heart failure \(Mild\) ‧25 mg ORALLY once daily, followed by an increase to 50 mg ORALLY once daily after 4 weeks if potassium level no more than 5 mmol/L was administered in a clinical trial |
| 肝功能異常 | 無需調整劑量  需調整劑量 |
| 腎功能異常 | 無需調整劑量  需調整劑量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Contraindicated 哺乳期使用禁忌 |
| 附帶說明 | micromedex:懷孕分級 B 哺乳Infant risk cannot be ruled out. 藥品仿單: 懷孕分級 C |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

